| Antigen: | CD19 |
| Clone: | BU12 |
| Subclass | IgG1 |
| Species Raised In: | Balb/c |
| Immunogen: | Human EB-4 Burkitt's lymphoma cell line |
| Cross Reactivity: | Human. |
| Applications: | FACS, Frozen, Immunoprecipitation |
| Growth Conditions: | RPMI 1640 + 10% FCS |
| Relevance: | CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase. |
| References: | Behr S. and Schriever F. 1995 J.Exp.Med. 182(5):1191-9. PMID: 7595190 Read more |
© Cancer Research Technology 2012